Improve Lung Cancer Treatment Outcomes

 

An online course for providers who care for patients with lung cancer.

NOW CME & CNA ACCREDITED

ENROLL NOW

Lung Cancer is actually a very heterogeneous disease that requires treatment individualised to both the specific patient and the specific tumour characteristics or biomarkers.

Now For ONLY $69!

 

You’re in the right place at the right moment because you know…

1


Lung cancer often recurs despite historically conventional treatment.

 

2


A large number of newer and very promising targeted therapy agents and immunotherapy agents have recently become approved for the treatment of lung cancer and may others are in the research pipeline.

 

3


Effective use of these agents requires both an organised working knowledge of of the available agents and a program of comprehensive biomarker testing.

 

Here's the Truth

 

 

Lung cancer is a life threatening disease

Treatment can be complicated and often require multiple modalities of therapeutic approaches

Every lung cancer is different just as every patient is different

Historically conventional treatment is often associated with a high recurrence rate

What if you could…

 

  • Have the knowledge you need to the optimal therapeutic decisions for your lung cancer patients that is individualised to both the patient and the tumour 
  • Have cutting edge information regarding these newer agents in an organised fashion from an experienced thoracic surgeon
  • Make timely decisions for optimal treatment strategies while armed with the best available data

 

 

So you can: 

 

 

  • Achieve the optimal outcomes using the best available treatment that is specific to your unique patients and their unique tumour characteristics
  • Know what is and what is not effective for the treatment of lung cancer in specific clinical situations and with specific tumour biomarker patterns

 

 

Module 1: Incidence and Mortality of NSCLC

Explore the prevalence and impact of Non-Small Cell Lung Cancer (NSCLC) through a detailed examination of incidence and mortality rates. Uncover key epidemiological factors contributing to the dynamics of NSCLC in this foundational module.

Module 2: Targeted Therapies

Delve into the molecular intricacies of targeted therapies for NSCLC with lessons covering various pathways such as EGFR, ALK, HER2, ROS1, RET, NTRK 1/2/3, BRAF V600E, MET exon 14, and KRAS G12C. Understand the mechanisms, potential benefits, and challenges associated with each targeted pathway

Module 3: Immunotherapy

Embark on an exploration of the burgeoning field of immunotherapy for NSCLC. Gain an overview of immunotherapy principles and understand the ongoing clinical trials that are shaping the landscape of NSCLC treatment through innovative immunotherapeutic approaches.

Module 4: Future Directions

Peer into the future of NSCLC treatment with lessons on targeted neoadjuvant treatment, interventions for very early-stage NSCLC (IA2-IA3), and investigative approaches in immunotherapy. Stay ahead of emerging trends and advancements in the dynamic landscape of NSCLC care.

Module 5: Immunotherapy

Recognize the pivotal role of biomarker testing in NSCLC management. Delve into the importance of biomarker testing in guiding treatment decisions and explore ongoing clinical trials that aim to push the boundaries of knowledge and treatment options for NSCLC.

ENROLL NOW